US › Healthcare

Sophia Genetics SA (SOPH)

US · Healthcare · Health Information Services

$8.53+6.96%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$23.3M

Revenue YoY

+27.2%

Net profit

$-22.4M

EPS

$-0.26

EPS estimate

$-0.15

Net margin

-95.9%

EPS came in at -0.26 against a street estimate of -0.15 — a miss of 73.3%.

Key statistics

Market cap

$677.6M

Forward P/E

0.0

P/B

8.05

Book value

$0.98

EPS (TTM)

$-1.17

52-week high

$8.98

52-week low

$3.15

50-day MA

$7.02

200-day MA

$5.46

Beta

0.98

Analyst view

Analysts rate Sophia Genetics SA a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $9.75.

Shareholding

Insiders

6.78%

Institutions

62.26%

Largest institutional holders

Fund	Stake
Generation Investment Management LLP	7.98%
AIGH Capital Management, LLC	4.64%
Akre Capital Management, LLC	4.37%
Principal Financial Group Inc	2.78%
Banque Pictet & Cie SA	2.59%
Royce & Associates, LP	2.13%
Soleus Capital Management, L.P.	1.84%
Alta Wealth Advisors LLC	1.66%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sophia Genetics SA — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.